Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Apr 14, 2021 10:05am
131 Views
Post# 32992079

RE:RE:RE:RE:The prescriber base has doubled for Trogarzo

RE:RE:RE:RE:The prescriber base has doubled for TrogarzoAt the end of fourth quarter they had $20,768,000 in cash, the net proceeds of the offering after fees was$42,668,000, in total they had $63,436,000 after the offering they have $56,716,000 in the bank. It looks like the cash burn was higher in the Q3/Q4 2020 than last quarter.


SPCEO1 wrote: My best guess on Q1 sales is they were likely biased lower because the company forced sales to the distributor system at the end of Q4 so they could have a good Q4 sales number to support the offering with the pre-announcement of good Q4 sales. Also, we are going to have to figure out where all the cash went. It looks like they burned through around $10 million in cash in a $15 million sales quarter. So, the OO likey led to nasty Q1 sales and was done in such a terrible way because they were blowing through their cash faster than we could have thought possible. On the cash, they raised $46 million, had around $20 million at last report and now have $57 million.
palinc2000 wrote: But unit sales are down?? What gives?

Bucknelly21 wrote: I heard that too palinic

 




<< Previous
Bullboard Posts
Next >>